UGT1A1 (TA)n PROMOTER GENOTYPE: DIAGNOSTIC AND POPULATION PHARMACOGENETIC MARKER IN SERBIA
Vukovic M, Radlovic N, Lekovic Z, Vucicevic K, Maric N, Kotur N, Gasic V, Ugrin M, Stojiljkovic M, Dokmanovic L, Zukic B, Pavlovic S
*Corresponding Author: Sonja Pavlovic, Ph.D., Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, PO BOX 23, 11010 Belgrade, Serbia. Tel: +38111-3976445. Fax: +38111-3975808. E-mail: sonya@sezampro.rs
page: 59

REFERENCES

1. Nagar S, Blanchard RL. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT)1A family members and its role in patient response to irinotecan. Drug Metab Rev. 2006; 38(3): 393-409. 2. Barbarino JM, Haidar CE, Klein TE, Altman RB. PharmGKB summary: Very important information for UGT1A1. Pharmacogenet Genomics. 2014; 24(3): 177-183. 3. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, et al. Thirteen UDP-glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics. 2001; 11(4): 357- 368. 4. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, et al. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem. 2000; 275(46): 36164-36171. 5. Strassburg CP, Nguyen N, Manns MP, Tukey RH. Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol. 1998; 54(4): 647-654. 6. Wisnumurti D, Sribudiani Y, Porsch RM, Maskoen AM, Abdulhamied LI, Rahayuningsih SE, et al. UGT1A1 genetic variations and haplotype associated with neonatal hyperbilirubinemia in Indonesian population. Biomed Res Int. 2018; 2018: 9425843. doi: 10.1155/2018/9425843. 7. Marques SC, Ikediobi ON. The clinical application of UGT1A1 pharmacogenetic testing: Gene-environment interactions. Hum Genomics. 2010; 4(4): 238-249. 8. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbertís syndrome. N Engl J Med. 1995; 333(18): 1171-1175. 9. Aono S, Adachi Y, Uyama E, Yamada Y, Keino H, Nanno T, et al. Analysis of genes for bilirubin UDPglucuronosyltransferase in Gilbertís syndrome. Lancet. 1995; 345(8955): 958-959. 10. Bosma P, Chowdhury JR, Jansen PH. Genetic inheritance of Gilbertís syndrome. Lancet. 1995; 346(8970): 314-315. 11. Radlović N. Hereditary hyperbilirubinemias. Srp Arh Celok Lek. 2014; 142(3-4): 257-260. 12. Radu P, Atsom J. Gilbertís syndrome-clinical and pharmacological implications. Isr Med Assoc J. 2001; 3(8): 593-598. 13. Radlović N, Leković Z, Mladenović M, Ristić D, Radlović V, Lekić V, et al. Gilbertís syndrome in children Ė Our experience. Srp Arh Celok Lek. 2007; 135(5-6): 317-320. 14. Radlović N, Ristić D, Brdar R, Janić N, Leković Z, Janić D, et al. Association of hereditary elliptocytosis and Gilbertís syndrome as the cause of biliary calculosis: Case report. Srp Arh Celok Lek. 2011; 139(5-6): 386-389. 15. Memon N, Weinberger BI, Hegyi T, Aleksunes LM. Inherited disorders of bilirubin clearance. Pediatr Res. 2016; 79(3): 378-386. 16. Pharmacogenomics Knowledge Base (https://www. pharmgkb.org) [accessed: April 10 2018] 17. Ha VH, Jupp J, Tsang RY. Oncology drug dosing in Gilbert Syndrome associated with UGT1A1: A summary of the literature. Pharmacotherapy. 2017; 37(8): 956-972. 18. de Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbertís syndrome. Gastroenterology. 1992; 102(2): 577-586. 19. Berg AO, Armstrong K, Botkin J, Calonge N, Haddow J, Kaye C, et al. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med. 2009; 11(1): 15-20. 20. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, et al. Mechanism of indinavir-induced hyper-bilirubinemia. Proc Natl Acad Sci USA. 2001; 98(22): 12671-12676. 21. Radojkovic D, Kusic J. Silver staining of denaturing gradient gel electrophoresis gels. Clin Chem. 2000; 46(6 Pt 1): 883-884. 22. Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, et al. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood. 2009; 113(14): 3307-3313. 23. Karan-Djurasevic T, Palibrk V, Kostic T, Spasovski V, Nikcevic G, Srzentic S, et al. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012; 12(4): 252-260. 24. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet. 2005; 76(5): 887-893. 25. Radoi VE, Ursu RI, Poenaru E, Arsene C, Bohiltea CL, Bohiltea R. Frequency of the UGT1A1*28 polymorphism in a Romanian cohort of Gilbert Syndrome individuals. J Gastrointestin Liver Dis. 2017; 26(1): 25-28. 26. Torres AK, Escartín N, Monzó C, Guzmán C, Ferrer I, González-Munoz C, et al. Genetic susceptibility to Gilbertís syndrome in a Valencian population; efficacy of the fasting test. Rev Clin Esp. 2017; 217(1): 1-6. 27. Viennas E, Komianou A, Mizzi C, Stojiljkovic M, Mitropoulou C, Muilu J, et al. Expanded national database collection and data coverage in the FINDbase worldwide database for clinically relevant genomic variation allele frequencies. Nucleic Acids Res. 2017; 45(D1): D846-D853. 28. Beutler E, Gelbart T, Demina A. Racial variability in the UDP glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA. 1998; 95(14): 8170-8174. 29. Premawardhena A, Fisher CA, Liu YT, Verma IC, de Silva S, Arambepola M, et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): Hematologic and evolutionary implications. Blood Cells Mol Dis. 2003; 31(1): 98-101. 30. Bajro MH, Josifovski T, Panovski M, Jankulovski N, Nestorovska AK, Matevska N, et al. Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. Cancer Genet. 2012; 205(4): 163-167. 31. Kapedanovska Nestorovska A, Jakovski K, Naumovska Z, Hiljadnikova Bajro M, Sterjev Z, Eftimov A, et al. Distribution of the most common genetic variants associated with a variable drug response in the population of the Republic of Macedonia. Balkan J Med Genet. 2015; 17(2): 5-14. 32. Marinković N, Pasalić D, Grsković B, Ferencak G, Honović L, Rukavina AS. Genotype frequencies of UDP-glucuronosyltransferase 1A1 promoter gene polymorphism in the population of healthy Croatian pre-scholars. Coll Antropol. 2008; 32(3): 725-729. 33. Mlakar SJ, Ostanek B. Development of a new DHPLC assay for genotyping UGT1A (TA)n polymorphism associated with Gilbertís syndrome. Biochem Med (Zagreb). 2011; 21(2): 167-173. 34. Ostanek B, Furlan D, Mavec T, Lukac-Bajalo J. UGT1A1(TA)n promoter polymorphism ó A new case of a (TA)8 allele in Caucasians. Blood Cells Mol Dis. 2007; 38(2): 78-82. 35. Biondi ML, Turri O, Dilillo D, Stival G, Guagnellini E. Contribution of the TATA-box genotype (Gilbert syndrome) to serum bilirubin concentrations in the Italian population. Clin Chem. 1999; 45(6 Pt 1): 897-898. 36. Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, Loriot MA, et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol. 2015; 29(3): 219-237. 37. Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, et al.; CPIC. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir prescribing. Clin Pharmacol Ther. 2016; 99(4): 363-369. 38. Culley CL, Kiang TK, Gilchrist SE, Ensom MH. Effect of the UGT1A1 28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: A systematic review. Ann Pharmacother. 2013; 47(4): 561-72. 39. Fujita K, Sugiyama M, Akiyama Y, Ando Y, Sasaki Y. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother Pharmacol. 2011; 67(1): 237-241. 40. de Souza MM, Vaisberg VV, Abreu RM, Ferreira AS, da Silva Ferreira C, Nasser PD, et al. UGT1A1 28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients: Outcomes from a case-control study. Medicine (Baltimore). 2017; 96(11): e6306.



Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Accepted articles (Accepted, unedited articles, published online and can be cited. The final edited and printed version of the manuscript will appear in future)
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006